Granules.ppt

8/17/2019 Granules.ppt

1/17

Granules India

Corporate Presentation


2/17

Vision

To be the global leader in

pharmaceutical manufacturing byprocess innovation and unparalleledeciencies

2


3/17

About Us• Granules is a pharmaceutical manufacturing company ith Active

Pharmaceutical Ingredients !API"# Pharmaceutical $ormulation

Intermediates !P$I" and $inished %osage !$%" facilities

• A leader in several &ey drugs including Paracetamol# Ibuprofen#'etformin# Guaifenesin and 'ethocarbamol

• $ounded in ()*+

• Publicly traded on the ,ombay -toc& ./change !012+*2" andational -toc& ./change !G3AU4.-"

• 3evenue in $5(1 is 3s6 78+ Cr6 !9(+0m"

• :or&force; (#Ventures# one ith ?ubei ,iocause# China and another ithA@inomoto mniChem# ,elgium

1


4/17

Core ,usiness -trategy• -igniBcant mar&et share ith large volumes in strategic molecules

•$ully integrated in &ey molecules from APIs to $inished %osages

• 3egulatory $ilings !A%As%ossier" for Global 'ar&ets

• Partner ith mar&et leaders

• Customer speciBc capacity allocation

• Unparalleled eciencies

+


5/17

Infrastructure vervie

• Granules has three facilities !plus to additional facilitiesthrough its =Vs"

• GranulesD $acilities !1"(6 Gagillapur E $inished %osage and P$I26 ,onthapally E %edicated Paracetamol API $acility

16 =eedimetla E 'ulti>Product API and P$I $acility

• =V $acilities !2"(6 =ingmen E %edicated Ibuprofen API $acility

26 ViFag E 'ulti>Product API $acility

• Total Capacity – API E 2


6/17

Gagillapur• $inished %osage and P$Is !Pharmaceutical $inished Intermediates"• P$I Capacity; (1#2$its E 0


7/17

,onthapally• %edicated Paracetamol API $acility

•

API Capacity; (1#


8/17

=eedimetla• 'ulti>Product API and P$I $acility

•

API Capacity; – 'etformin; 2#


9/17

=ingmen• %edicated Ibuprofen API $acility

•

perated by Granules ,iocause !0


10/17

ViFag• 'ulti>Product API $acility

•

perated by Granules mniChem!0


11/17

perational ./cellence• The CompanyKs . department focuses on continuous improvement6

Granules frames strategies to ensure eLectiveness in the

manufacturing process# minimiFe variation and aste6 The team hasalso improved throughput and reduced changeover time6

• GranulesD . department provides value to our customers byensuring consistent Muality# improving sustainability and meetingtheir groing needs

• The . team ensures a smooth process for site transfers

25% productivity

enhancement in

Paracetamol API

production

55% productivity

enhancement in

Guaifenesin API

production

3.6 million liter reduction

in waste water

2, ton reduction in

coal usa!e

" ton reduction of

caustic soda

Capacity Enhancements

during last 2 years

Sustainability Improvements

##% productivity

enhancement in

$etformin API

production

((


12/17

3evenue -ummary

(2


13/17

evenue yGeography

(1


14/17

evenue y us nessVertical

(+


15/17

rgChart

(0

MD

RegionalHead - USA

RegionalHead – EU,

CN, AU

RegionalHead –AMEA/ India

HeadStrategic

AccountManager

ED

CFO COO CMO Head HR Head ITHead

Strateg

Finance

Account!

Ta"ation

Co!ting

Co#$Secretar

HeadO$! –

%FI & FD

Head O$!- A%I

Head -SCM

Head,'A%FI & FDHead -OE

Head-%ro(ect!

C6 Jrishna Prasad

C6 ?arsha

VV- 'urthy ,6 'adhu -tefan 4ohle%r6 3a@

!Advisor" =itendra'ishra

%r6 Prasada3a@u

Tec)ad*i!or

'uraliprasad

Head,'A

A%I

+

Granulesmnichem

+

Granules,iocause


16/17

Granules 4eadership TeamMr. C. Krishna Prasad – Managing Director

$r. Prasad is the ounder of Granules and has three decades of e&perience in the pharmaceutical industry. In #'(), he set up

Paracetamol manufacturin! facility, which has *ecome one of the world+s reputed manufacturers of Paracetamol in e!ulated

$ar-ets. $r. Prasad pioneered and popularied the concept of Pharmaceutical ormulations Intermediates /PIs0 as a cost

efficient product for !lo*al formulations manufacturers.

Mr. arsha Chigurupati – E!ecutive Director

$r. 1hi!urupati has *een with Granules since 25 and served as 1$ from 262#. As 1$, $r. 1hi!urupati was

instrumental in commercialiin! the 1ompany+s inished 4osa!e 4ivision and also chan!ed the 1ompany+s focus to maruee

customers in the re!ulated mar-ets. As the &ecutive 4irector, $r. 1hi!urupati is responsi*le for the standalone operations of

Granules India includin! the P78

Mr. Madhusudan "ao – Chie# $perating $##icer

$r $adhusudan has over two decades of e&perience with !lo*al pharmaceutical companies. 9e previously served as 1 of

Glo*al Generics at rchid Pharmaceuticals where he was responsi*le for entire operations of Glo*al !enerics and 1A$:

*usinesses. Prior to that, $r ao wor-ed at 4r. eddy+s where he held various positions in Glo*al Generics Portfolio

$ana!ement ; Glo*al e!ulatory Affairs and 1ompliance; API


17/17

T?AJ 5U T?AJ 5U

(7

Granules.ppt

Documents

Transcript of Granules.ppt